Eli Lilly slips after crossing $1.1 trillion market value; Zepbound jumps 46%
Eli Lilly fell about 1.1% to $1,266.40, trimming market value to roughly $1.13 trillion after a record close. Zepbound rose 46% to $4.9 billion, gross margin reached 85.8%, and management raised full-year guidance. Mounjaro and Zepbound produced about $14.8 billion (64% of quarterly revenue), leaving pressure to expand capacity and defend pricing against rivals.